Clinical reference Biomarker Directory
Back to directory

BGLAP

Established

BGLAP encodes osteocalcin, a bone-formation marker used to monitor osteoporosis treatment.

Also known as Osteocalcin bone gamma-carboxyglutamic acid protein BGP
In plain language

Osteocalcin is a protein made by bone-building cells and reflects how active bone formation is. Beyond bones, some research suggests its undercarboxylated form may even influence insulin sensitivity, an unexpected role outside the skeleton.

Biomarker & context

BGLAP encodes osteocalcin, the most abundant non-collagenous protein in bone, secreted by osteoblasts during bone formation and serving as a marker of bone turnover.

What it indicates

Osteocalcin levels reflect bone formation activity; elevated levels occur in high bone-turnover states like growth or Paget's disease, while low levels suggest osteoporosis or vitamin K deficiency (since osteocalcin requires vitamin K for full function).

Diagnosis & clinical testing

Measured via serum immunoassay, typically alongside a bone resorption marker (like CTX) for a fuller bone-turnover picture; used to monitor antiresorptive therapy (bisphosphonates, denosumab) response in osteoporosis.

Guiding treatment

Serial osteocalcin can help confirm adequate response to osteoporosis treatment, typically alongside bone-specific alkaline phosphatase or CTX rather than as a stand-alone marker.

Clinical significance

A standard bone formation marker, often paired with a resorption marker like CTX for bisphosphonate monitoring.

References
  1. Walk-In Lab Resource Center. (2026). Osteocalcin.
  2. Frontiers in Endocrinology. Osteocalcin: Beyond Bones. (2024).